for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aslan Pharmaceuticals Ltd (ADR)

ASLN.OQ

Latest Trade

3.22USD

Change

0.00(-0.00%)

Volume

218,351

Today's Range

3.01

 - 

3.22

52 Week Range

1.43

 - 

6.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.22
Open
3.01
Volume
218,351
3M AVG Volume
20.20
Today's High
3.22
Today's Low
3.01
52 Week High
6.75
52 Week Low
1.43
Shares Out (MIL)
348.09
Market Cap (MIL)
223.86
Forward P/E
-6.85
Dividend (Yield %)
--

Latest Developments

More

Aslan Pharmaceuticals Posts Qtrly Loss Per Ordinary Share $0.02

Aslan Pharmaceuticals Reports Q1 Net Loss Of $6.7 mln

Aslan Pharmaceuticals Initiates Third Dose Cohort Of Aslan004 In Atopic Dermatitis Clinical Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aslan Pharmaceuticals Ltd (ADR)

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company is engaged in developing treatments to transform the lives of patients. The Company is developing ASLAN004, an antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), which is being developed for autoimmune disease. The Company's ASLAN004 is a fully human monoclonal antibody targeting the IL-13 receptor a1 subunit (IL-13Ra1). By targeting IL-13Ra1, which forms the Type II receptor complex with IL-4Ra, ASLAN004 inhibits signaling of both interleukin 4 (IL-4) and interleukin 13 (IL-13). IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, wheeze and cough.

Industry

Biotechnology & Drugs

Contact Info

83 Clemenceau Avenue, #12-03 Ue Square

239920

Singapore

+65.6.2224235

http://aslanpharma.com/zh/

Executive Leadership

Andrew James Howden

Chairman of the Board

Carl Firth

Chief Executive Officer, Director

Kiran Asarpota

Vice President-Finance

Alison Ward

Acting Vice President-R&D

Kenneth Kobayashi

Chief Medical Officer

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.400

2019

-1.450

2020

-0.400

2021(E)

-0.470
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.97
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
20.65
LT Debt To Equity (MRQ)
20.27
Return on Investment (TTM)
-43.81
Return on Equity (TTM)
-39.76

Latest News

Latest News

BRIEF-Aslan Pharmaceuticals Reports First Quarter 2020 Financial Results

* ASLAN PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up